First-in-class drug wins TGA tick

Posted 14 November 2022 AM

Last week the TGA waved through two innovative therapies including a dialysis product that CSL just recently added to its pipeline when it completed its mammoth Vifor Pharma acquisition.

The regulator approved the company's Korsuva, a first-in-class kappa opioid receptor agonist, indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.

To see the whole article, please login